YEAR-END REPORT 2013 CHRONTECH PHARMA

  · Research and development costs amounted to SEK 1.5 (13.9) m
  · Profit/loss after tax was SEK 7.5 (-19.7) m
  · Earnings per share were SEK 0.03 (-0.07)
  · Net sales SEK 15.1 (-) m
  · ChronTech has closed the deal concerning the sale of its hepatitis B and C
technologies to the Irish company Avac Pharma Ltd. This means that ChronTech has
received 625,000 USD, that the earlier loan of 625,000 USD has been assigned to
Avac Pharma Ltd, another 1 million USD will be paid on or before the first
anniversary of Closing. This payment amount to a total of 15.1 MSEK. Avac Pharma
Ltd will furthermore pay up to 1.5 million USD for the further development of
ChronTech’s injection technology IVIN.
  · The Swedish Companies Registration Office has during the period registered
the redemption of 80,274,295 shares in ChronTech Pharma AB.
  · ChronTech has carried out rights offering of shares and convertibles raising
approx. 9 MSEK before transaction costs. Both offerings were oversubscribed. As
of December 31, 2013 approx. 70 % of the convertibles have been converted into
interim shares.
  · ChronTech has applied for patent application for a new type of treatment of
hepatitis D (HDV).
  · ChronTech´s IVIN technology allows for lower vaccine doses with maintained
efficacy.

EVENTS AFTER THE END OF THE REPORTING PERIOD

  · ChronTechs therapeutic hepatitis D vaccine activates an immune response that
can enter the liver and eliminate liver cells that produce parts of HDV.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se

About ChronTech

ChronTech has developed and further develops a patent pending new type of
injection needle for a more effective uptake of genetic vaccines (IVIN) and
vaccine and therapy for hepatitis D. ChronTech also have part ownership in the
new platform technology RAS®. The ChronTech share is admitted to trade on First
North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.